DCM
TTPH

DAFNA Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

DAFNA Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,185
Closed -$446K – 98
2016
Q2 		$446K Buy
+5,185
New +$475K 0.35% 61

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DAFNA Capital Management's TTPH Position: Q3 2016 in Review

DAFNA Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2016, closing a stake of 5,185 shares — an estimated $446K sold.

DAFNA Capital Management first reported a position in TTPH in Q2 2016 and held it in 1 quarter. The position peaked at $446K in Q2 2016. 90 funds tracked by Wall St. Rank hold TTPH as of Q3 2016.

  • DAFNA Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 5,185 Tetraphase Pharmaceuticals, Inc. shares in Q3 2016, an estimated $446K.
  • DAFNA Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • DAFNA Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $446K in Q2 2016.
  • 90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.